MedIntelliBase� Breaking News - Fenofibrate (Cardiovascular Therapies)

IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics.

Fri, 01 Oct 2010 04:00:00 GMT

The goal of this study was to investigate the in vitro-in vivo correlation (IVIVC) for fenofibrate immediate release (IR) tablet formulations based on MeltDose-technique. The

Association of the -344C/T aldosterone synthase (CYP11B2) gene variant with hypertension and stroke.

Wed, 15 Sep 2010 04:00:00 GMT

Stroke is a complex disease caused by combination of multiple risk factors. Recent findings have suggested that stroke has a significant genetic component. Various types

Effect of Amlodipine + Candesartan on Cardiovascular Events in Hypertensive Patients With Coronary Artery Disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).

Wed, 15 Sep 2010 04:00:00 GMT

Combination therapy with calcium channel blockers and angiotensin II receptor blockers is recommended as one of the effective therapies for hypertension. However, it remains unclear

Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy.

Wed, 15 Sep 2010 04:00:00 GMT

Patients with mixed hyperlipidemia and at high risk of coronary heart disease may not achieve recommended low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol goals

Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells.

Sat, 11 Sep 2010 04:00:00 GMT

Heme oxygenase (HO)-1, which is the inducible isoform of the rate-limiting enzyme of heme degradation, has potent antioxidant and anti-inflammatory effects and is an emerging

Combination of Fenofibrate with Non-Statin Drug Regimens.

Tue, 07 Sep 2010 04:00:00 GMT

Objective: We present the available data on the effects of combined therapy of fenofibrate with drugs affecting lipid metabolism other than statins. Methods: We consider

Differential relationships between anthropometry measures and cardiovascular risk factors in boys and girls.

Mon, 06 Sep 2010 04:00:00 GMT

Abstract Objectives. The aim of the study was to compare commonly used anthropometry for cardiovascular risk factors in 14-year-olds. Methods. A total of 1 149

Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A prospective randomized double-blind clinical trial.

Wed, 01 Sep 2010 04:00:00 GMT

OBJECTIVE To assess the effects of inhibited gastrointestinal cholesterol absorption in statin-treated dyslipidemic patients. RESEARCH DESIGN AND METHODS In a multicenter prospective randomized double-blind placebo-controlled

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.

Wed, 01 Sep 2010 04:00:00 GMT

Pro-protein-convertase-subtilisin-kexin-9 (PCSK9) enhances the degradation of the low-density lipoprotein receptor (LDLR) that plays a major role in cholesterol homeostasis. Recent advances have revealed a large

Management of statin-intolerant high-risk patients.

Wed, 01 Sep 2010 04:00:00 GMT

Statins are an essential part of the management of patients at high vascular risk and are generally well-tolerated. However, statin intolerance will be observed more

Screening misses high LDL in many youths.

Wed, 01 Sep 2010 04:00:00 GMT

<< No Abstract Available >>

Differences in the association of cardiovascular risk factors with education: a comparison of Costa Rica (CRELES) and the USA (NHANES).

Wed, 01 Sep 2010 04:00:00 GMT

BACKGROUND: Despite different levels of economic development, Costa Rica and the USA have similar mortalities among adults. However, in the USA there are substantial differences

Impax Laboratories Confirms Patent Challenge Relating to VYTORIN(R), 10 mg/80 mg

Wed, 01 Sep 2010 04:00:00 GMT

Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by MSP Singapore Co. LLC in connection with VYTORIN(R) (ezetimibe/simvastatin), 10

Socioeconomic position, gender, health behaviours and biomarkers of cardiovascular disease and diabetes.

Wed, 01 Sep 2010 04:00:00 GMT

Socio-economic gradients in cardiovascular disease (CVD) and diabetes have been found throughout the developed world and there is some evidence to suggest that these gradients

Prevalence of insulin resistance and its relationship with cardiovascular disease risk factors among Thai adults over 35 years old.

Wed, 01 Sep 2010 04:00:00 GMT

AIMS: To estimate the prevalence of insulin resistance (HOMA-IR) and to study its relationship with selected cardiovascular disease risk factors among Thai adults. METHODS: This

Dietary patterns and cardiovascular risk markers in the UK Low Income Diet and Nutrition Survey.

Wed, 01 Sep 2010 04:00:00 GMT

BACKGROUND AND AIM: Dietary patterns have been associated with various disease risk markers. There is presently little representative data about the dietary patterns of adults

The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk.

Wed, 01 Sep 2010 04:00:00 GMT

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world. It encompasses a spectrum of disease ranging from

Effect of ezetimibe on carotid intimal thickness: the VYCTOR Study.

Wed, 01 Sep 2010 04:00:00 GMT

<< No Abstract Available >>

Effect of extended-release niacin or ezetimibe on carotid intimal thickness: the ARBITER-HALTS Study.

Wed, 01 Sep 2010 04:00:00 GMT

<< No Abstract Available >>

On the current debate on lowering LDL cholesterine with ezetimibe.

Wed, 01 Sep 2010 04:00:00 GMT

<< No Abstract Available >>